Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J’s Gorsky Promises Prioritization Of OTC Business

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson’s Q2 was another quarter of flat consumer products growth, with the return of some OTCs to market delayed until 2013. In his quarterly earnings call debut, CEO Alex Gorsky emphasized the firm’s commitment to diversification and restoring the supply of OTC products.

You may also be interested in...



J&J Consumer Business Picks Up, But Analysts See Long Road

J&J’s consumer business inched up 1% operationally in Q3, including about 6% growth at constant currency in OTC/nutritionals. However, costs associated with the remediation of McNeil OTC facilities are expected to weigh on J&J through most of 2013.

J&J Consumer Business Picks Up, But Analysts See Long Road

The consumer business inched up 1% operationally in Q3, including about 6% growth at constant currency in OTC/nutritionals. However, costs associated with the remediation of McNeil OTC facilities are expected to weigh on J&J through most of 2013.

J&J Consumer Business Picks Up, But Analysts See Long Road

The consumer business inched up 1% operationally in Q3, including about 6% growth at constant currency in OTC/nutritionals. However, costs associated with the remediation of McNeil OTC facilities are expected to weigh on J&J through most of 2013.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS105869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel